Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
The purpose of this study is to evaluate the safety profile and the effectiveness of etanercept under usual care settings in patients with PsA treated by dermatologists.
Skin Diseases, Papulosquamous
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prospective Post Marketing Surveillance To Evaluate The Safety And Efficacy Of Etanercept Under Usual Care Settings In Patients With Psoriatic Arthritis (Psa) Treated By Dermatologists|
- Determination of adverse events (AE) and serious adverse events (SAE) rates on etanercept therapy [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- Determination of response rate to Enbrel® in patients with Psoriatic Arthritis treated in a real life setting [ Time Frame: 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||January 2006|
|Study Completion Date:||February 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
|Patients with Psoriatic Arthritis||
The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Other Name: Enbrel
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician